alirocumab

Here's a look at the top tickers trending on StockTwits.com Regeneron: Net profit lower, sees Eylea growth This morning, Regeneron Pharmaceuticals (NASDAQ: REGN) reported its fourth quarter results. The company announced an EPS of $2.24, beating the consensus estimate of $2.08. Revenue of $...